Timothy Kopper
Concepts (65)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Spinal Cord Injuries | 4 | 2021 | 173 | 1.290 |
Why?
| Myelin Sheath | 2 | 2021 | 144 | 1.190 |
Why?
| Phospholipases A2, Cytosolic | 1 | 2021 | 6 | 0.760 |
Why?
| Microglia | 2 | 2021 | 202 | 0.670 |
Why?
| Macrophages | 5 | 2019 | 1267 | 0.650 |
Why?
| Inflammation | 4 | 2021 | 2485 | 0.600 |
Why?
| Azithromycin | 4 | 2021 | 80 | 0.590 |
Why?
| Macrophage Activation | 4 | 2021 | 164 | 0.590 |
Why?
| Phagocytosis | 2 | 2021 | 352 | 0.290 |
Why?
| Cytokines | 3 | 2021 | 1843 | 0.230 |
Why?
| Extracellular Vesicles | 1 | 2022 | 83 | 0.190 |
Why?
| Ketones | 1 | 2021 | 43 | 0.180 |
Why?
| Interleukin-4 | 1 | 2021 | 209 | 0.180 |
Why?
| Glioblastoma | 1 | 2022 | 253 | 0.170 |
Why?
| Leukemia Inhibitory Factor | 1 | 2018 | 6 | 0.160 |
Why?
| Infarction, Middle Cerebral Artery | 1 | 2018 | 38 | 0.160 |
Why?
| Reactive Oxygen Species | 1 | 2021 | 536 | 0.160 |
Why?
| Neuroprotective Agents | 1 | 2019 | 105 | 0.150 |
Why?
| Lipids | 1 | 2021 | 586 | 0.140 |
Why?
| Dementia, Vascular | 1 | 2016 | 16 | 0.140 |
Why?
| Disease Models, Animal | 3 | 2021 | 3545 | 0.130 |
Why?
| Nitric Oxide | 1 | 2021 | 827 | 0.130 |
Why?
| Neutrophils | 1 | 2021 | 1164 | 0.130 |
Why?
| Neurons | 2 | 2022 | 1284 | 0.120 |
Why?
| Brain Neoplasms | 1 | 2022 | 984 | 0.120 |
Why?
| Animals | 7 | 2021 | 31868 | 0.120 |
Why?
| Amyloid beta-Peptides | 1 | 2016 | 189 | 0.120 |
Why?
| Phenotype | 1 | 2021 | 2815 | 0.110 |
Why?
| Immunotherapy | 1 | 2016 | 474 | 0.100 |
Why?
| Recovery of Function | 1 | 2015 | 575 | 0.100 |
Why?
| Anti-Bacterial Agents | 2 | 2019 | 1477 | 0.090 |
Why?
| Mice | 3 | 2021 | 14928 | 0.080 |
Why?
| Mice, Inbred C57BL | 4 | 2019 | 4718 | 0.070 |
Why?
| Humans | 5 | 2022 | 115049 | 0.050 |
Why?
| Cell Line, Tumor | 2 | 2019 | 2716 | 0.050 |
Why?
| Immunomodulation | 1 | 2021 | 84 | 0.040 |
Why?
| Female | 3 | 2021 | 59617 | 0.040 |
Why?
| Lectins | 1 | 2018 | 44 | 0.040 |
Why?
| Interleukin-12 | 1 | 2019 | 110 | 0.040 |
Why?
| Statistics, Nonparametric | 1 | 2018 | 387 | 0.040 |
Why?
| Peptides | 1 | 2022 | 849 | 0.040 |
Why?
| Interleukin-10 | 1 | 2019 | 297 | 0.030 |
Why?
| Spleen | 1 | 2018 | 486 | 0.030 |
Why?
| Presenilin-1 | 1 | 2016 | 27 | 0.030 |
Why?
| Hyperhomocysteinemia | 1 | 2016 | 24 | 0.030 |
Why?
| CD11b Antigen | 1 | 2016 | 58 | 0.030 |
Why?
| Maze Learning | 1 | 2016 | 87 | 0.030 |
Why?
| Amyloid beta-Protein Precursor | 1 | 2016 | 54 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2018 | 344 | 0.030 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 299 | 0.030 |
Why?
| Lipopolysaccharides | 1 | 2018 | 817 | 0.030 |
Why?
| Interferon-gamma | 1 | 2018 | 723 | 0.030 |
Why?
| Up-Regulation | 1 | 2017 | 812 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2018 | 2212 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1322 | 0.030 |
Why?
| Gene Expression | 1 | 2017 | 1423 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2015 | 1857 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2016 | 1955 | 0.020 |
Why?
| Rats | 1 | 2018 | 4973 | 0.020 |
Why?
| RNA, Messenger | 1 | 2016 | 2563 | 0.020 |
Why?
| Time Factors | 1 | 2018 | 6141 | 0.020 |
Why?
| Cells, Cultured | 1 | 2015 | 3896 | 0.020 |
Why?
| Brain | 1 | 2018 | 2380 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2016 | 3118 | 0.020 |
Why?
| Male | 2 | 2018 | 55735 | 0.010 |
Why?
|
|
Kopper's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|